Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under VYNE Therapeutics Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is David Domzalski, President and Chief Executive Officer (Form 8-K filed 2026-07-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Bellevue Group Ag (filed 2026-10-07).
Who is behind it
Yarrow Bioscience, Inc.: incorporated in Delaware; business address in New Haven, Connecticut; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-07).
Officers and directors, each with the role and the filing that names them:
- DAVID DOMZALSKI: Executive Officer, Director (Form D, 2023-11-16)
- TYLER ZERONDA: Executive Officer (Form D, 2023-11-16)
- MUTYA HARSCH: Executive Officer (Form D, 2023-11-16)
- IAIN STUART: Executive Officer (Form D, 2023-11-16)
- STEVEN BASTA: Director (Form D, 2023-11-16)
- ANTHONY BRUNO: Director (Form D, 2023-11-16)
- ELISABETH SANDOVAL: Director (Form D, 2023-11-16)
- SHARON BARBARI: Director (Form D, 2023-11-16)
- PATRICK LEPORE: Director (Form D, 2023-11-16)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-07 | Bellevue Group Ag | 10.6% |
| Schedule 13G, 2026-09-17 | Raymond Debbane | 7.2% |
| Schedule 13G, 2026-08-14 | Adar1 Capital Management, LLC | 8.8% |
| Schedule 13G, 2026-08-14 | Venbio Global Strategic Fund V, L.P. | 9.99% |
| Schedule 13G/A, 2026-08-13 | Zhang Xiaofan | 0.6% |
| Schedule 13G, 2026-08-07 | Janus Henderson Group LTD. | 9.99% |
| Schedule 13G/A, 2026-08-07 | Logos Global Management LP | 10.7% |
| Schedule 13D, 2026-08-05 | Orbimed Advisors LLC | 9.97% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-28 | David Domzalski | President and Chief Executive Officer | departed | 2026-07-27 |
| Form 8-K, 2026-07-28 | Rebecca Frey | Chief Executive Officer | appointed |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-11-16 | $88.15M | $88.15M |
| Form D, 2022-11-18 | $300K | $300K |
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-07-28).
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/yarrow-bioscienceLast updated 2026-10-18
Primary record: Schedule 13G, 2026-10-07 · Form D, 2023-11-16 · Form 8-K, 2026-07-28 · Form D, 2022-11-18
Who owns Yarrow Bioscience, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/yarrow-bioscience